We are live on ! Find out more
FPF

FNY Partners Fund Portfolio holdings

AUM $185M Turnover 75.98%
1-Year Est. Return 32.58%
This Fund
S&P 500
This Quarter Est. Return
+14.16%
1 Year Est. Return
+32.58%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$588M
AUM Growth
+$175M
Cap. Flow
+$118M
Cap. Flow %
20.16%
Top 10 Hldgs %
54.34%
Holding
835
New
294
Increased
101
Reduced
91
Closed
281
Avg Time Held Equity + Options
0.2 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.2 years
Avg Time Held Equity only
0.3 years
Top 10 Avg Time Held Equity only
0.1 years
Top 20 Avg Time Held Equity only
0.2 years

Sector Composition

Rank Sector Weight
1 Healthcare 26.11%
2 Technology 14.68%
3 Communication Services 11.2%
4 Financials 9.54%
5 Consumer Staples 9.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
ISEE
701
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-3,000
Closed -$7K –
NYMX
702
DELISTED
Nymox Pharmaceutical Corp
NYMX
– –
-8,000
Closed -$35K –
BSMX
703
DELISTED
Banco Santander México, S, A., Institución de Banca Múltiple, Grupo Financiero Santander México
BSMX
– –
-1,000
Closed -$9K –
CLVS
704
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-4,000
Closed -$317K –
CLR
705
CALL
DELISTED
CONTINENTAL RESOURCES INC.
CLR
– –
-48
Closed -$1K –
CLR
706
DELISTED
CONTINENTAL RESOURCES INC.
CLR
– –
-2,000
Closed -$64K –
TWTR
707
CALL
DELISTED
Twitter, Inc.
TWTR
– –
-100
Closed -$1K –
HSTO
708
DELISTED
Histogen Inc. Common Stock
HSTO
– –
-99
Closed -$114K –
ALXN
709
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-251
Closed -$30K –
MDLY
710
DELISTED
Medley Management Inc
MDLY
– –
-250
Closed -$16K –
IPHI
711
DELISTED
INPHI CORPORATION
IPHI
– –
-5,550
Closed -$190K –
FIT
712
DELISTED
Fitbit, Inc. Class A common stock
FIT
$0 ﹤0.01%
+100
New +$582
2017 Q3
0 quarters
HDS
713
DELISTED
HD Supply Holdings, Inc.
HDS
– –
-500
Closed -$15K –
ENT
714
CALL
DELISTED
Global Eagle Entertainment Inc.
ENT
– –
-12
Closed -$1K –
PTLA
715
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-20
Closed -$1K –
RTN
716
DELISTED
Raytheon Company
RTN
– –
-500
Closed -$80K –
AKS
717
DELISTED
AK Steel Holding Corp
AKS
– –
-500
Closed -$3K –
INXN
718
DELISTED
Interxion Holding N.V.
INXN
– –
-700
Closed -$32K –
CPL
719
DELISTED
CPFL Energia S.A.
CPL
– –
-162
Closed -$2K –
MDCO
720
CALL
DELISTED
Medicines Co
MDCO
– –
-100
Closed -$3K –
MDCO
721
DELISTED
Medicines Co
MDCO
– –
-6,006
Closed -$228K –
BKJ
722
DELISTED
Bancorp of New Jersey, Inc.
BKJ
– –
-1,103
Closed -$15K –
CRZO
723
DELISTED
Carrizo Oil & Gas Inc
CRZO
– –
-1,000
Closed -$17K –
VIAB
724
PUT
DELISTED
Viacom Inc. Class B
VIAB
– –
-50
Closed -$1K –
NVLN
725
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
– –
-5,917
Closed -$54K –

Similar funds

FNY Partners Fund's Q3 2017 Portfolio in Review

As of Q3 2017, FNY Partners Fund held 835 positions worth $588M, up 42% from $413M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

FNY Partners Fund deployed $118M of net new capital in Q3 2017, opening 294 new positions and adding to 101 existing holdings. Its largest new stake was Kite Pharma, Inc.: 379,510 shares worth $68.2M.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets, up from 10% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Altaba Inc, an estimated $24.9M trimmed.

  • FNY Partners Fund's largest Q3 2017 buy was Kite Pharma, Inc.: 379,510 shares worth $68.2M.
  • FNY Partners Fund added most to Time Warner Inc in Q3 2017, an estimated $36.4M increase.
  • FNY Partners Fund's biggest Q3 2017 reduction was Altaba Inc, cutting an estimated $24.9M.
  • FNY Partners Fund fully exited Allied World Assurance Co Hld Lt in Q3 2017, selling an estimated $54.6M.
  • FNY Partners Fund's ten largest holdings make up 54% of its $588M portfolio in Q3 2017.
  • FNY Partners Fund opened 294 new positions and closed 281 in Q3 2017.
  • FNY Partners Fund's portfolio value rose 42% quarter-over-quarter to $588M.

Based on FNY Partners Fund's 13F filing for Q3 2017, filed 9 Nov 2017.